TAIPEI, Taiwan, October 1, 2025－TaiGen Biopharmaceuticals Holdings Ltd. (“TaiGen”) announces that TaiGen Biotechnology, a subsidiary company of TaiGen, have signed an exclusive licensing agreement with Vietnamese pharmaceutical companies Fideschem Inc. and Newsun Pharmaceutical JSC. for the rights to develop and commercialize the novel antibiotic Taigexyn® in Vietnam.

Under the agreement, Taigexyn capsules and injections are licensed for 20 years in Vietnam, with Fideschem handling strategic coordinator and regulatory support, and Newsun providing nationwide hospital and pharmacy distribution. Their complementary strengths are expected to speed up market entry and broaden Taigexyn’s reach.

Dr. Kuo-Lung Huang, Chairman of TaiGen Biopharmaceuticals, stated:
" Taigexyn is indicated for community-acquired pneumonia (CAP), which represents 12% of all pneumonia cases in Vietnam. Pneumonia ranks as Vietnam’s 2nd most prevalent disease after hypertension, with an incidence of 561 cases per 100,000 population, highlighting strong demand for effective treatments and new therapeutic options."

According to the World Health Organization (WHO), Vietnam recorded 270,000 deaths related to antimicrobial resistance (AMR) between 2020 and 2023, making it one of the countries most severely affected by AMR worldwide and the second highest in AMR-related mortality in the Western Pacific region, posing a heavy burden on the public healthcare system.

About Fideschem Inc. and Newsun Pharmaceutical JSC.
Fideschem Inc., originally established as an API distributors, has expanded into finished pharmaceuticals with a portfolio covering antibiotics, metabolic disorders, oncology, and other therapeutic areas. Newsun Pharmaceutical JSC. is a pharmaceutical distributor and agent in Vietnam, with a product range that spans antibiotics, cardiovascular, neurological, metabolic, and pain management drugs. Its distribution network covers hospitals and pharmacies nationwide.

About TaiGen Biotechnology Co. Ltd.
Founded in 2001 and listed on the Taiwan OTC Market in 2014, TaiGen Biotechnology is a fully integrated pharmaceutical company focused on innovative small-molecule drugs, particularly anti-infectives. The company has expertise in drug discovery, development, regulatory approval, and multi-country clinical trials, with experience in overseas licensing. Its flagship antibiotic, Taigexyn® (Nemonoxacin), is approved in Taiwan, China, and Russia, while the influenza antiviral TG-1000 has completed Phase III trials and filed an NDA in China.